Table A1.
Race/Ethnicity | No. of Deaths | Model One* |
Model Two† |
Model Three‡ |
Model Four§ |
||||
---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | ||
White (reference) | 2,004 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
Black v white | 308 | 1.83 | 1.62 to 2.07 | 1.10 | 0.77 to 1.59 | 1.19 | 0.83 to 1.72 | 1.11 | 0.97 to 1.27 |
Asian v white | 39 | 0.62 | 0.45 to 0.85 | 0.64 | 0.46 to 0.88 | 0.60 | 0.43 to 0.83 | 0.56 | 0.37 to 0.85 |
Hispanic v white | 139 | 1.04 | 0.87 to 1.25 | 0.86 | 0.71 to 1.03 | 0.80 | 0.67 to 0.97 | 0.59 | 0.42 to 0.82 |
Abbreviation: HR, hazard ratio.
Age adjusted: age at diagnosis, National Comprehensive Cancer Network center, and year of diagnosis.
Model one plus socioeconomic factors: insurance type, educational attainment, employment status, menopausal status, comorbidity score, and body mass index.
Model two plus tumor characteristics: stage at diagnosis, triggering event, tumor grade, estrogen receptor status, progesterone receptor status, and human epidermal growth factor receptor 2 status.
Model three plus treatment: chemotherapy, hormonal therapy, and trastuzumab use.